Loading...
XKRX
085660
Market cap367mUSD
Jul 10, Last price  
10,200.00KRW
1D
3.66%
1Q
-42.05%
Jan 2017
-19.69%
IPO
-36.58%
Name

Chabiotech Co Ltd

Chart & Performance

D1W1MN
XKRX:085660 chart
P/E
P/S
0.45
EPS
Div Yield, %
Shrs. gr., 5y
5.04%
Rev. gr., 5y
13.79%
Revenues
1.27t
+21.36%
449,260,920,351417,459,627,558488,599,592,162534,611,811,539664,716,825,657727,476,086,769844,582,867,317953,951,423,1301,045,049,021,0001,268,253,669,000
Net income
-109.88b
L+1,264.26%
16,879,880,491-46,503,150,41024,389,270,16846,374,602,061-18,658,191,055-13,968,474,442-47,542,787,807-8,431,247,321-8,053,909,000-109,876,118,000
CFO
-72.10b
L+45.53%
18,048,903,59513,848,928,67177,336,122,00428,180,929,59250,078,154,75423,015,270,621-22,118,668,25713,018,244,730-49,546,239,000-72,103,512,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Chabiotech Co.,Ltd. is a global biotechnology firm specializing in the development of cell and gene therapies, particularly those involving stem and immune cells, with operations in South Korea and internationally. The company's comprehensive offerings include umbilical cord blood storage for treating intractable conditions, alongside various regenerative medicine solutions. It also manages storage services for immune and stem cells, provides anti-aging treatments, and delivers therapeutic solutions for debilitating illnesses. Furthermore, Chabiotech runs medical wellness initiatives encompassing fitness, spa services, and nutritional supplements. Leveraging its extensive research and development as well as clinical expertise, the company provides customized services covering product development, manufacturing, clinical trials, and commercialization. Chabiotech assists clients with optimizing IT system infrastructure and operations, and offers consulting services for the establishment, management, and growth of its proprietary Chaum model. Additionally, the company provides solutions for maternal-focused genomic testing and personalized healthcare. It is actively engaged in developing advanced immune cell therapies, such as CBT101 for recurrent glioblastoma and solid cancers, and both CBT111 and CAR-NK treatments specifically targeting solid tumors. Its stem cell pipeline features CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for addressing macular degeneration and Stargardt's disease. Beyond its core bio-pharmaceutical activities, Chabiotech also offers IVF (fertility) services, manufactures cosmetics and their raw materials, supplies medical devices, provides bioinsurance storage, and conducts various research services. Established in 2002, the company maintains its headquarters in Seoul, South Korea.
IPO date
Dec 27, 2005
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT